Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Dietz J, et al. Among authors: schott e. Gastroenterology. 2018 Mar;154(4):976-988.e4. doi: 10.1053/j.gastro.2017.11.007. Epub 2017 Nov 13. Gastroenterology. 2018. PMID: 29146520
Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection.
Mas Marques A, Mueller T, Welke J, Taube S, Sarrazin C, Wiese M, Halangk J, Witt H, Ahlenstiel G, Spengler U, Goebel U, Schott E, Weich V, Schlosser B, Wasmuth HE, Lammert F, Berg T, Schreier E. Mas Marques A, et al. Among authors: schott e. Infect Genet Evol. 2009 Sep;9(5):847-52. doi: 10.1016/j.meegid.2009.05.002. Epub 2009 May 14. Infect Genet Evol. 2009. PMID: 19446659
Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection.
Fischer J, Böhm S, Scholz M, Müller T, Witt H, George J, Sarrazin C, Susser S, Schott E, Suppiah V, Booth DR, Stewart GJ, van Bömmel F, Brodzinski A, Fülöp B, Migaud P, Berg T. Fischer J, et al. Among authors: schott e. Hepatology. 2012 Jun;55(6):1700-10. doi: 10.1002/hep.25582. Epub 2012 Apr 18. Hepatology. 2012. PMID: 22234924
Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection.
Fischer J, Böhm S, Müller T, Witt H, Sarrazin C, Susser S, Migaud P, Schott E, Stewart G, Brodzinski A, Fülöp B, van Bömmel F, George J, Berg T. Fischer J, et al. Among authors: schott e. PLoS One. 2013 Oct 29;8(10):e77530. doi: 10.1371/journal.pone.0077530. eCollection 2013. PLoS One. 2013. PMID: 24204859 Free PMC article.
TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.
Erhardt A, Kolligs F, Dollinger M, Schott E, Wege H, Bitzer M, Gog C, Lammert F, Schuchmann M, Walter C, Blondin D, Ohmann C, Häussinger D. Erhardt A, et al. Among authors: schott e. Cancer Chemother Pharmacol. 2014 Nov;74(5):947-54. doi: 10.1007/s00280-014-2568-8. Epub 2014 Aug 31. Cancer Chemother Pharmacol. 2014. PMID: 25173458 Clinical Trial.
Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study.
Hofmann WP, Mauss S, Lutz T, Schober A, Böker K, Moog G, Baumgarten A, Pfeiffer-Vornkahl H, Alshuth U, Hüppe D, Wedemeyer H, Manns MP, Schott E. Hofmann WP, et al. Among authors: schott e. PLoS One. 2015 Jul 31;10(7):e0134839. doi: 10.1371/journal.pone.0134839. eCollection 2015. PLoS One. 2015. PMID: 26230998 Free PMC article.
237 results